{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-296814","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2023-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.852644+00:00","generated_at":"2026-06-07T11:48:05.042176+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Syndax announces $200M public offering of common stock at $18.50/share","bullets":["Issued 10,810,810 shares at $18.50; gross proceeds ~$200M ($230M with overallotment).","Underwriters: Goldman Sachs, J.P. Morgan, Cowen and Company; deal expected to close Dec. 19, 2023.","Lock-up agreement: company, directors, officers, certain stockholders restricted for 60 days.","Offering made under existing S-3 shelf registration (File 333-254661)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-296814","json":"https://secwatch.observer/filing/0001193125-23-296814.json","markdown":"https://secwatch.observer/filing/0001193125-23-296814.md","text":"https://secwatch.observer/filing/0001193125-23-296814.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000119312523296814/0001193125-23-296814-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000119312523296814/d50500d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:48:05.042176+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"babc435ad7349fe17c2ba2953b2c6606447c55bb","claim":"Syndax Pharmaceuticals Inc entered into Underwriting Agreement with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters valued at approximately $200.0 million (effective 2023-12-14).","evidence_excerpt":"On December 14, 2023, Syndax Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters (collectively, the “ Underwriters ”), relating to the issuance and sale of 10,810,810 shares of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), at a price to the public of $18.50 per share (the “ Offering ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312523296814/0001193125-23-296814-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters"},{"label":"Value","value":"approximately $200.0 million"},{"label":"Effective","value":"2023-12-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}